Our Insights Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More Oncology Anthony Iannacci 8/7/25 Oncology Anthony Iannacci 8/7/25 Enhertu is poised to dominate first-line HER2+ breast cancer Read More Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More Oncology Anthony Iannacci 3/26/20 Oncology Anthony Iannacci 3/26/20 Enhertu: A New Leader in Later-Line Breast Cancer Read More Want to get in touch? Click here
Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More
Oncology Anthony Iannacci 8/7/25 Oncology Anthony Iannacci 8/7/25 Enhertu is poised to dominate first-line HER2+ breast cancer Read More
Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More
Oncology Anthony Iannacci 3/26/20 Oncology Anthony Iannacci 3/26/20 Enhertu: A New Leader in Later-Line Breast Cancer Read More
